Literature DB >> 9831411

Clinical use of cisapride and its risk-benefit in paediatric patients.

Y Vandenplas1.   

Abstract

This paper provides a comprehensive review of the current knowledge on cisapride in different clinical conditions in children: different manifestations of gastro-oesophageal reflux, such as (excessive) regurgitation, oesophagitis, chronic respiratory disease or uncontrolled asthma, cystic fibrosis, chronic dyspepsia, constipation and pseudo-obstruction, and as an aid to small bowel capsule-biopsy. It discusses, in depth, the safety profile of cisapride in paediatric patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831411     DOI: 10.1097/00042737-199810000-00011

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

1.  Should cisapride have been "blacklisted"?

Authors:  M Markiewicz; Y Vanden Plas
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-01       Impact factor: 5.747

2.  Chronic Idiopathic Intestinal Pseudo-obstruction.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

3.  Diagnosis and treatment of gastroesophageal reflux disease in infants and children.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

Review 4.  Efficacy and tolerability of cisapride in children.

Authors:  Y Vandenplas; A Benatar; F Cools; A Arana; B Hegar; B Hauser
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

5.  Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients.

Authors:  V Mertens; K Blondeau; A Pauwels; R Farre; B Vanaudenaerde; R Vos; G Verleden; D E Van Raemdonck; L J Dupont; D Sifrim
Journal:  Dig Dis Sci       Date:  2009-02-25       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.